On Tysabri sales - they said units grew by 6% year-over-year in the U.S. but number of new patients was somewhat lower than last quarter. On the JCV immunoassay, they need the data from the ongoing STRATIFY studies to get the test approved. They are planning to submit labeling changes by the first quarter of next year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.